Amgen Inc (AMGN) 153.98 $AMGN
You Can't Keep Volatility Down Forever
at The Street - Wed Aug 26, 1:00PM CDT
We saw this coming, but there's more to the recent turmoil than China.
BIIB: 298.25 (+16.51), HACK: 27.14 (+0.93), GILD: 106.96 (+4.40), BHP: 34.08 (+1.16), LH: 117.80 (+3.04), AMGN: 153.98 (+8.79)
Biotech Stock Roundup: Acorda Gains on Patent Issues, Vital Crushed by Liver Data
Arpita Dutt - Zacks Investment Research - Wed Aug 26, 7:55AM CDT
It was a mixed week for the biotech sector with companies like Acorda (ACOR) and BioMarin (BMRN) providing positive updates while others saw their share prices crashing on disappointing data.
BIIB: 298.25 (+16.51), BMRN: 128.10 (+6.96), VTL: 3.31 (-0.11), MCUR: 3.44 (-0.23), AMGN: 153.98 (+8.79), ACOR: 31.96 (+0.59), ALKS: 60.07 (+2.54)
Amgen files for approval of parathyroid disorder drug
AP - Tue Aug 25, 12:13PM CDT
NEW YORK (AP) — Biotech drugmaker Amgen said Tuesday it filed for marketing approval of a drug designed to treat a symptom of chronic kidney disease.
AMGN: 153.98 (+8.79)
Amgen To Present New Long-Term Repatha(TM) (Evolocumab) Data Analysis At ESC Congress 2015
PR Newswire - Tue Aug 25, 8:15AM CDT
Amgen (NASDAQ:AMGN) today announced that it will present six abstracts at the upcoming ESC Congress 2015, organized by the European Society of Cardiology, being held Aug. 29 - Sept. 2 in London. Data will be presented evaluating RepathaTM (evolocumab), a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor approved in the European Union (EU) for the treatment of patients with uncontrolled cholesterol who require additional intensive low-density lipoprotein cholesterol (LDL-C) reduction.1
AMGN: 153.98 (+8.79)
Amgen Submits New Drug Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416)
PR Newswire - Tue Aug 25, 8:00AM CDT
Amgen (NASDAQ: AMGN) today announced the submission of a New Drug Application (NDA) with the United States Food and Drug Administration (FDA) for etelcalcetide (formerly AMG 416) for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) on hemodialysis. If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously at the end of the dialysis session.
AMGN: 153.98 (+8.79)
After Yesterday's Decline of 4.87%, Amgen Offers Investors Better Value
Comtex SmarTrend(R) - Mon Aug 24, 5:21PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $140.00 to a high of $154.42. Yesterday, the shares fell 4.9%, which took the trading range below the 3-day low of $155.19 on volume of 8.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AMGN: 153.98 (+8.79)
Amgen Falls 4.87% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Aug 24, 5:20PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $140.00 to a high of $154.42. Yesterday, the shares fell 4.9%, which took the trading range below the 3-day low of $155.19 on volume of 8.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AMGN: 153.98 (+8.79)
Halozyme Enzyme Could Boost Power Of Cancer Drugs
at Investor's Business Daily - Mon Aug 24, 7:02AM CDT
Halozyme Therapeutics has been one of 2015's hotter biotech stocks, but it's not exactly because of developing a drug. Halozyme's (HALO) one marketed product, Hylenex, aids in the delivery of injectable drugs. Halozyme has also licensed Enhanze for...
JNJ: 95.11 (+4.38), HALO: 17.46 (+0.58), PFE: 32.43 (+1.09), AMGN: 153.98 (+8.79), ABBV: 63.14 (+2.43), BXLT: 35.45 (+0.72), CELG: 119.23 (+6.53)
4 Reasons To Keep An Eye On Top Biotech Celgene
at Investor's Business Daily - Fri Aug 21, 5:06PM CDT
Celgene has pulled back as the market has come under increased selling pressure, but the long-term prospects for the biotech leader remain healthy. Celgene (CELG) develops cancer and immune-inflammatory-related disease therapies, including multiple...
BIIB: 298.25 (+16.51), RCPT: 231.99 (+0.04), AMGN: 153.98 (+8.79), JUNO: 36.50 (+0.69), REGN: 535.47 (+36.45), CELG: 119.23 (+6.53)
Don't Let Fear Freeze You At The Right Moment To Buy
at Investor's Business Daily - Fri Aug 21, 4:49PM CDT
October 1990 was a scary time for investors, and for that matter, the United States. Would you have had the courage to buy stocks? If so, you could have been handsomely rewarded. A great rally awaited you. So when a market decline has gotten quite...
AMGN: 153.98 (+8.79)
Why Eli Lilly (LLY) was a Bright Spot in the Market on Thursday
Arpita Dutt - Zacks Investment Research - Fri Aug 21, 1:45PM CDT
Eli Lilly (LLY) scored a big win in its long-term CV outcomes study.
GILD: 106.96 (+4.40), AMGN: 153.98 (+8.79), LLY: 81.10 (+2.84), REGN: 535.47 (+36.45)
'Fast Money' Recap: Why Fear Ruled the Markets
at The Street - Fri Aug 21, 4:00AM CDT
The trading panel discussed why investors let emotion overrule logic, whether to buy 'FANG' stocks and Hewlett-Packard earnings.
NFLX: 110.13 (+8.61), AMZN: 500.77 (+34.40), IBM: 146.70 (+5.74), FB: 87.19 (+4.19), M: 58.72 (+1.95), IBB: 341.75 (+16.49), DIS: 99.23 (+3.34), AMGN: 153.98 (+8.79), GOOGL: 659.74 (+47.27), IWM: 112.48 (+2.79), HPQ: 27.10 (+1.41)
Look for Shares of Amgen to Potentially Rebound after Yesterday's 3.25% Sell Off
Comtex SmarTrend(R) - Thu Aug 20, 4:02PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $161.03 to a high of $165.50. Yesterday, the shares fell 3.3%, which took the trading range below the 3-day low of $164.45 on volume of 3.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AMGN: 153.98 (+8.79)
Watch for Amgen to Potentially Rebound After Falling 3.25% Yesterday
Comtex SmarTrend(R) - Thu Aug 20, 4:02PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $161.03 to a high of $165.50. Yesterday, the shares fell 3.3%, which took the trading range below the 3-day low of $164.45 on volume of 3.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AMGN: 153.98 (+8.79)
This Is a Concern That Amgen Investors Shouldn't Take Lightly
Sean Williams, The Motley Fool - Motley Fool - Thu Aug 20, 10:02AM CDT
Source: Amgen via Flickr. Overall, Amgen shareholders have had little to complain about since the end of the recession. Amgen shares have more than tripled in value, and the company is in the midst of an unprecedented growth spurt that has it...
ESRX: 84.10 (+3.18), VVUS: 1.12 (+0.07), CVS: 102.87 (+2.87), AMGN: 153.98 (+8.79), SNY: 49.13 (+1.30), REGN: 535.47 (+36.45)
AG Frosh: Drug Company Unlawfully Marketed Drugs
M2 - Thu Aug 20, 3:39AM CDT
Attorney General Brian E. Frosh today announced that Maryland, joined by 47 other states and the District of Columbia, entered into a $71 million settlement with Amgen Inc., to resolve allegations that the pharmaceutical company made illegal and unsubstantiated claims about two of its products.
AMGN: 153.98 (+8.79)
Intelligence on: Conjugation Platform Technologies 2015 - Detailed Insights on Future Opportunities
M2 - Thu Aug 20, 3:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nszlzs/intelligence_on) has announced the addition of the "Intelligence on: Conjugation Platform Technologies" report to their offering. The unprecedented success of antibody drug conjugates have lead to a rapid increase in the number of clinical stage candidates. The majority of these first generation ADCs rely on the well validated platforms developed by Seattle Genetics and ImmunoGen. For the industry to continue its rapid development new technologies are essential to increase diversity of approaches, improve the safety and efficacy of the drugs, and target new indications and exploit novel mechanisms of action. 'Intelligence on: Conjugation Platform Technologies' is a scientific report, produced for researchers to review the different technology approaches developed to date and the levels of commercial and scientific validation that has been done on specific platforms. This report focuses on reviewing the available linker and payload technologies suitable for antibody-drug conjugates. Discover what opportunities there are within the global landscape, learn what new conjugation approaches are emerging and read expert perspectives on what the future holds for the field. Providing sought after intelligence on the variety of emerging technologies for antibody drug conjugation, detailed insights will be shared on future opportunities, potential applications as well as current commercial and scientific validation. Key Topics Covered: 1. Introduction, scopes and objectives 2. Antibody conjugates and other payloads 3. Linker technologies 4. Payload platforms 5. Improving payload delivery mechanisms 6. IP challenges, deal structures, mergers and acquisitions; future opportunities 7. Interviews with experts in the field Companies Mentioned - ADC Therapeutics - AREVA Med - Abbvie - Abzena - Actinium Pharmaceuticals - Adimab - Affinicon - Agensys - Algeta - Allozyne - Alpha Cancer Technologies - Ambrx - Amgen - Angiochem - Asana Biosciences - Aspyrian Therapeutics - Astellas - AstraZeneca - BMS - Baxter - Bayer - BiOasis Technologies - BioAlta - Biogen Idec - Biotest - Boehringer Ingelheim - Cancer Research UK - Catalent - Celgene - Celldex - Cellerant Therapeutics - Centrose - Centyrex - Covagen For more information visit http://www.researchandmarkets.com/research/ns...ligence_on
BIIB: 298.25 (+16.51), ATNM: 1.93 (unch), AMGN: 153.98 (+8.79), CELGZ: 1.68 (+0.12)
Is Esperion's Good News Actually Bad?
Todd Campbell, The Motley Fool - Motley Fool - Wed Aug 19, 12:39PM CDT
Source: Flickr user stockmonkeys.com. FDA regulators met with Esperion Therapeutics to discuss phase 2 results for the cholesterol-busting drug ETC-1002, and the company reported that the FDA won't require a long-and-costly...
ESPR: 52.85 (+2.59), AMGN: 153.98 (+8.79), REGN: 535.47 (+36.45)
Biotech Stock Roundup: Kite Addresses Patient Death Concerns, Omeros Soars on Data
Arpita Dutt - Zacks Investment Research - Wed Aug 19, 7:33AM CDT
Kite Pharma (KITE) provided an update on KTE-C19 and remains on track to provide data later this year at ASH.
BIIB: 298.25 (+16.51), KITE: 51.53 (+1.49), AMGN: 153.98 (+8.79), AAVL: 10.51 (+0.43), ABBV: 63.14 (+2.43), OMER: 16.25 (-0.32)
AG Frosh: Drug Company Unlawfully Marketed Drugs Settlement requires Amgen to change marketing practices
M2 - Wed Aug 19, 4:36AM CDT
AG Frosh: Drug Company Unlawfully Marketed Drugs
AMGN: 153.98 (+8.79)
You Can't Keep Volatility Down Forever
at The Street - Wed Aug 26, 1:00PM CDT
We saw this coming, but there's more to the recent turmoil than China.
BIIB: 298.25 (+16.51), HACK: 27.14 (+0.93), GILD: 106.96 (+4.40), BHP: 34.08 (+1.16), LH: 117.80 (+3.04), AMGN: 153.98 (+8.79)
Biotech Stock Roundup: Acorda Gains on Patent Issues, Vital Crushed by Liver Data
Arpita Dutt - Zacks Investment Research - Wed Aug 26, 7:55AM CDT
It was a mixed week for the biotech sector with companies like Acorda (ACOR) and BioMarin (BMRN) providing positive updates while others saw their share prices crashing on disappointing data.
BIIB: 298.25 (+16.51), BMRN: 128.10 (+6.96), VTL: 3.31 (-0.11), MCUR: 3.44 (-0.23), AMGN: 153.98 (+8.79), ACOR: 31.96 (+0.59), ALKS: 60.07 (+2.54)
Amgen files for approval of parathyroid disorder drug
AP - Tue Aug 25, 12:13PM CDT
NEW YORK (AP) — Biotech drugmaker Amgen said Tuesday it filed for marketing approval of a drug designed to treat a symptom of chronic kidney disease.
AMGN: 153.98 (+8.79)
Amgen To Present New Long-Term Repatha(TM) (Evolocumab) Data Analysis At ESC Congress 2015
PR Newswire - Tue Aug 25, 8:15AM CDT
Amgen (NASDAQ:AMGN) today announced that it will present six abstracts at the upcoming ESC Congress 2015, organized by the European Society of Cardiology, being held Aug. 29 - Sept. 2 in London. Data will be presented evaluating RepathaTM (evolocumab), a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor approved in the European Union (EU) for the treatment of patients with uncontrolled cholesterol who require additional intensive low-density lipoprotein cholesterol (LDL-C) reduction.1
AMGN: 153.98 (+8.79)
Amgen Submits New Drug Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416)
PR Newswire - Tue Aug 25, 8:00AM CDT
Amgen (NASDAQ: AMGN) today announced the submission of a New Drug Application (NDA) with the United States Food and Drug Administration (FDA) for etelcalcetide (formerly AMG 416) for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) on hemodialysis. If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously at the end of the dialysis session.
AMGN: 153.98 (+8.79)
After Yesterday's Decline of 4.87%, Amgen Offers Investors Better Value
Comtex SmarTrend(R) - Mon Aug 24, 5:21PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $140.00 to a high of $154.42. Yesterday, the shares fell 4.9%, which took the trading range below the 3-day low of $155.19 on volume of 8.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AMGN: 153.98 (+8.79)
Amgen Falls 4.87% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Aug 24, 5:20PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $140.00 to a high of $154.42. Yesterday, the shares fell 4.9%, which took the trading range below the 3-day low of $155.19 on volume of 8.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AMGN: 153.98 (+8.79)
Halozyme Enzyme Could Boost Power Of Cancer Drugs
at Investor's Business Daily - Mon Aug 24, 7:02AM CDT
Halozyme Therapeutics has been one of 2015's hotter biotech stocks, but it's not exactly because of developing a drug. Halozyme's (HALO) one marketed product, Hylenex, aids in the delivery of injectable drugs. Halozyme has also licensed Enhanze for...
JNJ: 95.11 (+4.38), HALO: 17.46 (+0.58), PFE: 32.43 (+1.09), AMGN: 153.98 (+8.79), ABBV: 63.14 (+2.43), BXLT: 35.45 (+0.72), CELG: 119.23 (+6.53)
4 Reasons To Keep An Eye On Top Biotech Celgene
at Investor's Business Daily - Fri Aug 21, 5:06PM CDT
Celgene has pulled back as the market has come under increased selling pressure, but the long-term prospects for the biotech leader remain healthy. Celgene (CELG) develops cancer and immune-inflammatory-related disease therapies, including multiple...
BIIB: 298.25 (+16.51), RCPT: 231.99 (+0.04), AMGN: 153.98 (+8.79), JUNO: 36.50 (+0.69), REGN: 535.47 (+36.45), CELG: 119.23 (+6.53)
Don't Let Fear Freeze You At The Right Moment To Buy
at Investor's Business Daily - Fri Aug 21, 4:49PM CDT
October 1990 was a scary time for investors, and for that matter, the United States. Would you have had the courage to buy stocks? If so, you could have been handsomely rewarded. A great rally awaited you. So when a market decline has gotten quite...
AMGN: 153.98 (+8.79)
Why Eli Lilly (LLY) was a Bright Spot in the Market on Thursday
Arpita Dutt - Zacks Investment Research - Fri Aug 21, 1:45PM CDT
Eli Lilly (LLY) scored a big win in its long-term CV outcomes study.
GILD: 106.96 (+4.40), AMGN: 153.98 (+8.79), LLY: 81.10 (+2.84), REGN: 535.47 (+36.45)
'Fast Money' Recap: Why Fear Ruled the Markets
at The Street - Fri Aug 21, 4:00AM CDT
The trading panel discussed why investors let emotion overrule logic, whether to buy 'FANG' stocks and Hewlett-Packard earnings.
NFLX: 110.13 (+8.61), AMZN: 500.77 (+34.40), IBM: 146.70 (+5.74), FB: 87.19 (+4.19), M: 58.72 (+1.95), IBB: 341.75 (+16.49), DIS: 99.23 (+3.34), AMGN: 153.98 (+8.79), GOOGL: 659.74 (+47.27), IWM: 112.48 (+2.79), HPQ: 27.10 (+1.41)
Look for Shares of Amgen to Potentially Rebound after Yesterday's 3.25% Sell Off
Comtex SmarTrend(R) - Thu Aug 20, 4:02PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $161.03 to a high of $165.50. Yesterday, the shares fell 3.3%, which took the trading range below the 3-day low of $164.45 on volume of 3.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AMGN: 153.98 (+8.79)
Watch for Amgen to Potentially Rebound After Falling 3.25% Yesterday
Comtex SmarTrend(R) - Thu Aug 20, 4:02PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $161.03 to a high of $165.50. Yesterday, the shares fell 3.3%, which took the trading range below the 3-day low of $164.45 on volume of 3.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AMGN: 153.98 (+8.79)
This Is a Concern That Amgen Investors Shouldn't Take Lightly
Sean Williams, The Motley Fool - Motley Fool - Thu Aug 20, 10:02AM CDT
Source: Amgen via Flickr. Overall, Amgen shareholders have had little to complain about since the end of the recession. Amgen shares have more than tripled in value, and the company is in the midst of an unprecedented growth spurt that has it...
ESRX: 84.10 (+3.18), VVUS: 1.12 (+0.07), CVS: 102.87 (+2.87), AMGN: 153.98 (+8.79), SNY: 49.13 (+1.30), REGN: 535.47 (+36.45)
AG Frosh: Drug Company Unlawfully Marketed Drugs
M2 - Thu Aug 20, 3:39AM CDT
Attorney General Brian E. Frosh today announced that Maryland, joined by 47 other states and the District of Columbia, entered into a $71 million settlement with Amgen Inc., to resolve allegations that the pharmaceutical company made illegal and unsubstantiated claims about two of its products.
AMGN: 153.98 (+8.79)
Intelligence on: Conjugation Platform Technologies 2015 - Detailed Insights on Future Opportunities
M2 - Thu Aug 20, 3:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nszlzs/intelligence_on) has announced the addition of the "Intelligence on: Conjugation Platform Technologies" report to their offering. The unprecedented success of antibody drug conjugates have lead to a rapid increase in the number of clinical stage candidates. The majority of these first generation ADCs rely on the well validated platforms developed by Seattle Genetics and ImmunoGen. For the industry to continue its rapid development new technologies are essential to increase diversity of approaches, improve the safety and efficacy of the drugs, and target new indications and exploit novel mechanisms of action. 'Intelligence on: Conjugation Platform Technologies' is a scientific report, produced for researchers to review the different technology approaches developed to date and the levels of commercial and scientific validation that has been done on specific platforms. This report focuses on reviewing the available linker and payload technologies suitable for antibody-drug conjugates. Discover what opportunities there are within the global landscape, learn what new conjugation approaches are emerging and read expert perspectives on what the future holds for the field. Providing sought after intelligence on the variety of emerging technologies for antibody drug conjugation, detailed insights will be shared on future opportunities, potential applications as well as current commercial and scientific validation. Key Topics Covered: 1. Introduction, scopes and objectives 2. Antibody conjugates and other payloads 3. Linker technologies 4. Payload platforms 5. Improving payload delivery mechanisms 6. IP challenges, deal structures, mergers and acquisitions; future opportunities 7. Interviews with experts in the field Companies Mentioned - ADC Therapeutics - AREVA Med - Abbvie - Abzena - Actinium Pharmaceuticals - Adimab - Affinicon - Agensys - Algeta - Allozyne - Alpha Cancer Technologies - Ambrx - Amgen - Angiochem - Asana Biosciences - Aspyrian Therapeutics - Astellas - AstraZeneca - BMS - Baxter - Bayer - BiOasis Technologies - BioAlta - Biogen Idec - Biotest - Boehringer Ingelheim - Cancer Research UK - Catalent - Celgene - Celldex - Cellerant Therapeutics - Centrose - Centyrex - Covagen For more information visit http://www.researchandmarkets.com/research/ns...ligence_on
BIIB: 298.25 (+16.51), ATNM: 1.93 (unch), AMGN: 153.98 (+8.79), CELGZ: 1.68 (+0.12)
Is Esperion's Good News Actually Bad?
Todd Campbell, The Motley Fool - Motley Fool - Wed Aug 19, 12:39PM CDT
Source: Flickr user stockmonkeys.com. FDA regulators met with Esperion Therapeutics to discuss phase 2 results for the cholesterol-busting drug ETC-1002, and the company reported that the FDA won't require a long-and-costly...
ESPR: 52.85 (+2.59), AMGN: 153.98 (+8.79), REGN: 535.47 (+36.45)
Biotech Stock Roundup: Kite Addresses Patient Death Concerns, Omeros Soars on Data
Arpita Dutt - Zacks Investment Research - Wed Aug 19, 7:33AM CDT
Kite Pharma (KITE) provided an update on KTE-C19 and remains on track to provide data later this year at ASH.
BIIB: 298.25 (+16.51), KITE: 51.53 (+1.49), AMGN: 153.98 (+8.79), AAVL: 10.51 (+0.43), ABBV: 63.14 (+2.43), OMER: 16.25 (-0.32)
AG Frosh: Drug Company Unlawfully Marketed Drugs Settlement requires Amgen to change marketing practices
M2 - Wed Aug 19, 4:36AM CDT
AG Frosh: Drug Company Unlawfully Marketed Drugs
AMGN: 153.98 (+8.79)
